Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 100

1.

Successful Outcome of Autologous Stem Cell Transplantation for Relapsed or Refractory Germ Cell Tumors.

Mousavi SA, Abedinzadeh N, Taj L, Kasaeian A, Alimoghaddam K, Vaezi M, Zokaasadi M, Kamranzadeh Fumani H, Ghavamzadeh A.

Int J Hematol Oncol Stem Cell Res. 2018 Jul 1;12(3):192-196.

2.

High-dose chemotherapy with autologous stem cell transplantation in relapsed or refractory germ cell tumours: outcomes and prognostic variables in a case series of 17 patients.

Lewin J, Dickinson M, Voskoboynik M, Collins M, Ritchie D, Toner G.

Intern Med J. 2014 Aug;44(8):771-8. doi: 10.1111/imj.12486.

PMID:
24893627
3.

[High dose chemotherapy with autologous stem-cell support in germ cell tumors: The Instituto Português de Oncologia de Lisboa Francisco Gentil Series].

Brito M, Sanchez P, Velho S, Miranda N, Leal da Costa F, Ferreira I, Teixeira G, Guimarães A, Abecasis M, Passos Coelho JL.

Acta Med Port. 2011 Jul-Aug;24(4):533-44. Epub 2011 Dec 12. Portuguese.

4.

A phase II trial of high-dose chemotherapy (HDCT) supported by hematopoietic stem-cell transplantation (HSCT) in germ-cell tumors (GCTs) patients failing cisplatin-based chemotherapy: the Multicentric TAXIF II study.

Selle F, Wittnebel S, Biron P, Gravis G, Roubaud G, Bui BN, Delva R, Bay JO, Fléchon A, Geoffrois L, Caty A, Soares DG, de Revel T, Fizazi K, Gligorov J, Micléa JM, Dubot C, Provent S, Temby I, Gaulet M, Horn E, Brindel I, Lotz JP.

Ann Oncol. 2014 Sep;25(9):1775-82. doi: 10.1093/annonc/mdu198. Epub 2014 Jun 3.

PMID:
24894084
5.

High-dose chemotherapy followed by autologous stem cell transplantation for patients with relapsed/refractory Hodgkin lymphoma.

Rancea M, Monsef I, von Tresckow B, Engert A, Skoetz N.

Cochrane Database Syst Rev. 2013 Jun 20;(6):CD009411. doi: 10.1002/14651858.CD009411.pub2. Review.

PMID:
23784872
6.

High-Dose Chemotherapy and Autologous Peripheral-Blood Stem-Cell Transplantation for Relapsed Metastatic Germ Cell Tumors: The Indiana University Experience.

Adra N, Abonour R, Althouse SK, Albany C, Hanna NH, Einhorn LH.

J Clin Oncol. 2017 Apr 1;35(10):1096-1102. doi: 10.1200/JCO.2016.69.5395. Epub 2016 Nov 21.

7.

Bevacizumab/high-dose chemotherapy with autologous stem-cell transplant for poor-risk relapsed or refractory germ-cell tumors.

Nieto Y, Tu SM, Bassett R, Jones RB, Gulbis AM, Tannir N, Kingham A, Ledesma C, Margolin K, Holmberg L, Champlin R, Pagliaro L.

Ann Oncol. 2015 Oct;26(10):2125-32. doi: 10.1093/annonc/mdv310. Epub 2015 Jul 21. Erratum in: Ann Oncol. 2015 Dec;26(12):2507-8.

8.

Autologous stem-cell transplantation for poor-risk and relapsed intermediate- and high-grade non-Hodgkin's lymphoma.

Nademanee A, Molina A, Dagis A, Snyder DS, O'Donnell MR, Parker P, Stein A, Smith E, Planas I, Kashyap A, Spielberger R, Fung H, Krishnan A, Bhatia R, Wong KK, Somlo G, Margolin K, Chow W, Sniecinski I, Vora N, Slovak M, Niland JC, Forman SJ.

Clin Lymphoma. 2000 Jun;1(1):46-54.

PMID:
11707813
9.

Risk-Stratified Initial Salvage Therapy for Relapsed or Refractory Metastatic Germ Cell Tumors.

Narayan V, Gunnarsson O, Hwang WT, Squillante CM, Nathanson KL, Stadtmauer EA, Vaughn DJ.

Clin Genitourin Cancer. 2016 Dec;14(6):524-529. doi: 10.1016/j.clgc.2016.03.015. Epub 2016 Mar 24.

PMID:
27083130
10.

Salvage high-dose chemotherapy in female patients with relapsed/refractory germ-cell tumors: a retrospective analysis of the European Group for Blood and Marrow Transplantation (EBMT).

De Giorgi U, Richard S, Badoglio M, Kanfer E, Bourrhis JH, Nicolas-Virelizier E, Vettenranta K, Lioure B, Martin S, Dreger P, Schuler MK, Thomson K, Scarpi E, Rosti G, Selle F, Mangili G, Lanza F, Bregni M; Solid Tumours Working Party (STWP) of the EBMT.

Ann Oncol. 2017 Aug 1;28(8):1910-1916. doi: 10.1093/annonc/mdx259.

PMID:
28510616
11.

Treatment outcome of relapsed/refractory primary central nervous system diffuse large B-cell lymphoma: a single-center experience of autologous stem cell transplantation.

Choi MK, Kang ES, Kim DW, Ko YH, Seok H, Park JH, Pyo DH, Hoon Lim D, Kim SJ, Kim WS.

Int J Hematol. 2013 Sep;98(3):346-54. doi: 10.1007/s12185-013-1403-z. Epub 2013 Jul 19.

PMID:
23868695
12.

Myeloablative chemotherapy and autologous stem cell transplantation in patients with relapsed or progressed central nervous system germ cell tumors: results of Korean Society of Pediatric Neuro-Oncology (KSPNO) S-053 study.

Baek HJ, Park HJ, Sung KW, Lee SH, Han JW, Koh KN, Im HJ, Kang HJ, Park KD.

J Neurooncol. 2013 Sep;114(3):329-38. doi: 10.1007/s11060-013-1188-1. Epub 2013 Jul 4.

PMID:
23824533
13.

Salvage high-dose chemotherapy for germ cell tumors.

Feldman DR, Powles T.

Urol Oncol. 2015 Aug;33(8):355-62. doi: 10.1016/j.urolonc.2015.01.025. Epub 2015 Mar 30. Review.

PMID:
25837842
14.

High-dose chemotherapy followed by hematological support: experience in the treatment of germ cell tumors.

Pico JL, Fadel E, Ibrahim A, Bourhis JH, Droz JP.

Bull Cancer. 1995;82 Suppl 1:56s-60s. Review.

PMID:
7542945
15.

Long-term outcome of autologous stem-cell transplantation in relapsed or refractory Hodgkin's lymphoma.

Sirohi B, Cunningham D, Powles R, Murphy F, Arkenau T, Norman A, Oates J, Wotherspoon A, Horwich A.

Ann Oncol. 2008 Jul;19(7):1312-9. doi: 10.1093/annonc/mdn052. Epub 2008 Mar 19.

PMID:
18356139
16.

High-Dose Chemotherapy and Peripheral Hematopoietic Stem Cell Transplantation in Relapsed/Refractory Hodgkin's Lymphoma.

Kelta M, Zekri J, Abdelghany E, Ur Rehman J, Khan ZA, Al-Saadi R, Dada R.

Tumori. 2016 Dec 1:tj5000591. doi: 10.5301/tj.5000591. [Epub ahead of print]

PMID:
28009428
17.

Chemoresistance can be overcome with high-dose chemotherapy and autologous stem-cell transplantation for relapsed and refractory Hodgkin lymphoma.

Gerrie AS, Power MM, Shepherd JD, Savage KJ, Sehn LH, Connors JM.

Ann Oncol. 2014 Nov;25(11):2218-23. doi: 10.1093/annonc/mdu387. Epub 2014 Aug 22.

PMID:
25149708
18.

High-dose therapy with autologous stem cell transplantation versus chemotherapy or immuno-chemotherapy for follicular lymphoma in adults.

Schaaf M, Reiser M, Borchmann P, Engert A, Skoetz N.

Cochrane Database Syst Rev. 2012 Jan 18;1:CD007678. doi: 10.1002/14651858.CD007678.pub2. Review.

PMID:
22258971
19.

Treatment outcomes for older patients with relapsed/refractory aggressive lymphoma receiving salvage chemotherapy and autologous stem cell transplantation are similar to younger patients: a subgroup analysis from the phase III CCTG LY.12 trial.

Davison K, Chen BE, Kukreti V, Couban S, Benger A, Berinstein NL, Kaizer L, Desjardins P, Mangel J, Zhu L, Djurfeldt MS, Hay AE, Shepherd LE, Crump M.

Ann Oncol. 2017 Mar 1;28(3):622-627. doi: 10.1093/annonc/mdw653.

PMID:
27993811
20.

Survival outcomes of patients with germ cell tumors treated with high-dose chemotherapy for refractory or relapsing disease.

Zschäbitz S, Distler FA, Krieger B, Wuchter P, Schäfer-Eckart K, Jenzer M, Hohenfellner M, Dreger P, Haag GM, Jäger D, Pahernik S, Grüllich C.

Oncotarget. 2018 Apr 27;9(32):22537-22545. doi: 10.18632/oncotarget.25162. eCollection 2018 Apr 27.

Supplemental Content

Support Center